Sign in
WithdrawnPhase 2

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Key facts

Who runs it
Y-mAbs Therapeutics
Where
Hong Kong, Russia, Singapore, and South Korea9 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
2 Dec 2021
Expected to end
Apr 2027
Type of study
Interventional
Treatments tested
  • Naxitamab
  • GM-CSF
  • Isotretinoin
Record updated
1 September 2022
Why it stopped
Study terminated due to business priorities

Who can take part

Age
1 year and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Documentet neuroblastoma at time of diagnosis defined as; Histopathology of solid tumor biopsy, or; Bone marrow aspirate or biopsy indicative of neuroblastoma plus high blood or urine catecholamine metabolite levels
  • Documented high-risk disease at time of initial diagnosis defined as; MYNC-amplified at stage L2, M or MS (according to International Neuroblastoma Risk Group (INRG)) of any age or; MYCN-nonamplified with stage M (according to INRG) and diagnosed at ≥ 18 months of age or
  • Patient must have completed frontline therapy, and achieved one of the following:; verified complete response according to INRC (bone marrow positive minimal residual disease is allowed as assessed by RTqPCR at site) after completion of induction and consolidation with or without autologous stem cell transplantation; Verified partial response according to INRC for primary site and soft tissue, bone, and bone marrow metastases at pre-autologous stem cell transplantation evaluation (i.e., myeloablative chemotherapy + autologous stem cell transplantation required as part of frontline regimen). Furthermore, bone marrow response must be with ≤ 5% tumor (of total nucleated cellular content) seen on any specimen from a bilateral bone marrow aspirate/biopsy and bone response must be with ≤ 3 areas of abnormal uptake on 123I-MIBG scintigraphy
  • Age ≥ 12 months at trial enrollment

Who cannot take part

  • Any systemic anti-cancer therapy, including chemotherapy, within 3 weeks prior to enrollment
  • Autologous stem cell transplantation within 6 weeks prior to enrollment or ongoing toxicity caused by the autologous stem cell transplantation at the discretion of the Investigator
  • Therapeutic 131I-MIBG within 6 weeks prior to enrollment
  • Prior anti-GD2 therapy
  • Verified progressive disease during induction or consolidation therapy
  • Performance status of < 50% as per the Lansky scale (patients less than 16 years of age) or Karnofsky scale (patients aged 16 years or older)

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.

The group in the trial

  • naxitamab + GM-CSF + isotretinoinTreatment being tested

    8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin

    Treatment: Naxitamab, GM-CSF, and Isotretinoin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label,Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial
Record updated
1 September 2022